FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321016188> ?p ?o ?g. }

• W4321016188 endingPage "104477" @default.
• W4321016188 startingPage "104477" @default.
• W4321016188 abstract "PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of the early longitudinal CA-125 kinetics could be used as a pragmatic indicator of the subsequent rucaparib efficacy, like it is for platinum-based chemotherapy.The datasets of ARIEL2 and Study 10 involving recurrent HGOC patients treated with rucaparib were retrospectively investigated. The same strategy as those successfully developed for platinum chemotherapy, based on CA-125 ELIMination rate constant K (KELIM™), was implemented. Individual values of rucaparib-adjusted KELIM (KELIM-PARP) were estimated based on the longitudinal CA-125 kinetics during the first 100 treatment days, and then scored as favorable (KELIM-PARP ≥1.0) or unfavorable (KELIM-PARP <1.0). The prognostic value of KELIM-PARP regarding treatment efficacy (radiological response, and progression-free survival (PFS)) was assessed using univariable/multivariable analyses, with respect to platinum-sensitivity and homologous recombination deficiency (HRD) status.The data from 476 patients were assessed. The CA-125 longitudinal kinetics during the first 100-treatment days could be accurately assessed using the KELIM-PARP model. In patients with platinum-sensitive diseases, BRCA mutational status KELIM-PARP score and were associated with subsequent complete/partial radiological responses (KELIM-PARP: odds-ratio = 2.81, 95% CI 1.86-4.52), and PFS (KELIM-PARP: hazard-ratio = 0.67, 95% CI 0.50-0.91). The patients with BRCA-wild type cancer and favorable KELIM-PARP experienced long PFS with rucaparib regardless of HRD. In platinum-resistant disease patients, KELIM-PARP was associated with subsequent radiological response (odds-ratio = 2.80, 95% CI 1.82-4.72).This proof-of-concept study confirms the early CA-125 longitudinal kinetics during rucaparib in recurrent HGOC patients are assessable by mathematical modeling, to generate individual a KELIM-PARP score associated with the subsequent efficacy. This pragmatic strategy might be useful for selecting the patients for PARPi-based combination regimens, when identifying efficacy biomarker is challenging. Further assessment of this hypothesis is warranted.The present study was supported by Clovis Oncology with a grant to academic research association." @default.
• W4321016188 created "2023-02-17" @default.
• W4321016188 creator A5003877775 @default.
• W4321016188 creator A5039041353 @default.
• W4321016188 creator A5058238015 @default.
• W4321016188 creator A5064757320 @default.
• W4321016188 creator A5069918197 @default.
• W4321016188 creator A5073787373 @default.
• W4321016188 creator A5082234321 @default.
• W4321016188 creator A5084420374 @default.
• W4321016188 creator A5085758096 @default.
• W4321016188 creator A5088144652 @default.
• W4321016188 date "2023-03-01" @default.
• W4321016188 modified "2023-09-25" @default.
• W4321016188 title "Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10" @default.
• W4321016188 cites W1935237200 @default.
• W4321016188 cites W2002710053 @default.
• W4321016188 cites W2066464642 @default.
• W4321016188 cites W2088050133 @default.
• W4321016188 cites W2095523635 @default.
• W4321016188 cites W2108090432 @default.
• W4321016188 cites W2111437716 @default.
• W4321016188 cites W2121322385 @default.
• W4321016188 cites W2128868545 @default.
• W4321016188 cites W2199466904 @default.
• W4321016188 cites W2557666746 @default.
• W4321016188 cites W2592948192 @default.
• W4321016188 cites W2751912349 @default.
• W4321016188 cites W2775990182 @default.
• W4321016188 cites W2930540768 @default.
• W4321016188 cites W3012975398 @default.
• W4321016188 cites W3047848114 @default.
• W4321016188 cites W3048967410 @default.
• W4321016188 cites W3084464523 @default.
• W4321016188 cites W3089768241 @default.
• W4321016188 cites W3135337095 @default.
• W4321016188 cites W3159728738 @default.
• W4321016188 cites W3163378364 @default.
• W4321016188 cites W3166231492 @default.
• W4321016188 cites W3200484435 @default.
• W4321016188 cites W3203448690 @default.
• W4321016188 cites W3204509441 @default.
• W4321016188 cites W4200267402 @default.
• W4321016188 cites W4229453381 @default.
• W4321016188 cites W4285595457 @default.
• W4321016188 cites W4286602983 @default.
• W4321016188 cites W4291011829 @default.
• W4321016188 cites W4306661079 @default.
• W4321016188 doi "https://doi.org/10.1016/j.ebiom.2023.104477" @default.
• W4321016188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36801617" @default.
• W4321016188 hasPublicationYear "2023" @default.
• W4321016188 type Work @default.
• W4321016188 citedByCount "0" @default.
• W4321016188 crossrefType "journal-article" @default.
• W4321016188 hasAuthorship W4321016188A5003877775 @default.
• W4321016188 hasAuthorship W4321016188A5039041353 @default.
• W4321016188 hasAuthorship W4321016188A5058238015 @default.
• W4321016188 hasAuthorship W4321016188A5064757320 @default.
• W4321016188 hasAuthorship W4321016188A5069918197 @default.
• W4321016188 hasAuthorship W4321016188A5073787373 @default.
• W4321016188 hasAuthorship W4321016188A5082234321 @default.
• W4321016188 hasAuthorship W4321016188A5084420374 @default.
• W4321016188 hasAuthorship W4321016188A5085758096 @default.
• W4321016188 hasAuthorship W4321016188A5088144652 @default.
• W4321016188 hasBestOaLocation W43210161881 @default.
• W4321016188 hasConcept C121608353 @default.
• W4321016188 hasConcept C126322002 @default.
• W4321016188 hasConcept C143998085 @default.
• W4321016188 hasConcept C207103383 @default.
• W4321016188 hasConcept C2776694085 @default.
• W4321016188 hasConcept C2780427987 @default.
• W4321016188 hasConcept C44249647 @default.
• W4321016188 hasConcept C50382708 @default.
• W4321016188 hasConcept C71924100 @default.
• W4321016188 hasConceptScore W4321016188C121608353 @default.
• W4321016188 hasConceptScore W4321016188C126322002 @default.
• W4321016188 hasConceptScore W4321016188C143998085 @default.
• W4321016188 hasConceptScore W4321016188C207103383 @default.
• W4321016188 hasConceptScore W4321016188C2776694085 @default.
• W4321016188 hasConceptScore W4321016188C2780427987 @default.
• W4321016188 hasConceptScore W4321016188C44249647 @default.
• W4321016188 hasConceptScore W4321016188C50382708 @default.
• W4321016188 hasConceptScore W4321016188C71924100 @default.
• W4321016188 hasLocation W43210161881 @default.
• W4321016188 hasLocation W43210161882 @default.
• W4321016188 hasLocation W43210161883 @default.
• W4321016188 hasOpenAccess W4321016188 @default.
• W4321016188 hasPrimaryLocation W43210161881 @default.
• W4321016188 hasRelatedWork W1967715255 @default.
• W4321016188 hasRelatedWork W2082636730 @default.
• W4321016188 hasRelatedWork W2120574916 @default.
• W4321016188 hasRelatedWork W2360606572 @default.
• W4321016188 hasRelatedWork W2391729578 @default.
• W4321016188 hasRelatedWork W2761925198 @default.
• W4321016188 hasRelatedWork W2783585287 @default.
• W4321016188 hasRelatedWork W2994686985 @default.
• W4321016188 hasRelatedWork W3047309708 @default.
• W4321016188 hasRelatedWork W4242937576 @default.

• next